FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 57019

News■ Unclear/unknown

Astrocyte Pharmaceuticals Secures $9.5 Million Series B to Advance Phase 2 Clinical Development of Breakthrough TBI and Concussion Therapy AST-004

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-30 10:00 UTC
LAST UPDATE2026-09-30 10:00 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

A $9.5M Series B for a private biotech is small and pre-revenue, with topline data still pending.

Early-stage private raise, no public read
CATALYST TO WATCH

Winter topline concussion trial results

MAIN RISK

Phase 2 failure would erase the thesis

FULL DISPATCH

Enrollment Complete in STARFAST Sports-Related Concussion Trial; Topline Results Expected This Winter GROTON, Conn., Sept. 30, 2026 /PRNewswire/ -- Astrocyte Pharmaceuticals Inc., a pioneering clinical-stage biotechnology company developing first-in-class cerebroprotective therapies for...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-09-30 10:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.